Inflammation & Immunity
XBiotech's Vilamakitug Clears FDA IND Review for Phase II Axial SpA Trial
The 30-day FDA review with no clinical hold signals a clear regulatory path forward for the IL-1α–targeting monoclonal …
The 30-day FDA review with no clinical hold signals a clear regulatory path forward for the IL-1α–targeting monoclonal …